Abstract

Background and objectivesThe impact of the newly proposed pathological classification by the Japan Renal Pathology Society (JRPS) on renal outcome is unclear. So we evaluated that impact and created a new pathological scoring to predict outcome using this classification.Design, setting, participants, & measurementsA multicenter cohort of 493 biopsy-proven Japanese patients with diabetic nephropathy (DN) were analyzed. The association between each pathological factor—Tervaert’ and JRPS classifications—and renal outcome (dialysis initiation or 50% eGFR decline) was estimated by adjusted Cox regression. The overall pathological risk score (J-score) was calculated, whereupon its predictive ability for 10-year risk of renal outcome was evaluated.ResultsThe J-scores of diffuse lesion classes 2 or 3, GBM doubling class 3, presence of mesangiolysis, polar vasculosis, and arteriolar hyalinosis were, respectively, 1, 2, 4, 1, and 2. The scores of IFTA classes 1, 2, and 3 were, respectively, 3, 4, and 4, and those of interstitial inflammation classes 1, 2, and 3 were 5, 5, and 4 (J-score range, 0–19). Renal survival curves, when dividing into four J-score grades (0–5, 6–10, 11–15, and 16–19), were significantly different from each other (p<0.01, log-rank test). After adjusting clinical factors, the J-score was a significant predictor of renal outcome. Ability to predict 10-year renal outcome was improved when the J-score was added to the basic model: c-statistics from 0.661 to 0.685; category-free net reclassification improvement, 0.154 (-0.040, 0.349, p = 0.12); and integrated discrimination improvement, 0.015 (0.003, 0.028, p = 0.02).ConclusionsMesangiolysis, polar vasculosis, and doubling of GBM—features of the JRPS system—were significantly associated with renal outcome. Prediction of DN patients’ renal outcome was better with the J-score than without it.

Highlights

  • Diabetic nephropathy (DN) is one of the main causes of end-stage renal disease (ESRD)—and probably among the most challenging kidney diseases—in many countries worldwide [1]

  • Renal biopsy is sometimes helpful for patients who have only short histories of diabetes, have no diabetic retinopathy, or do have massive hematuria, since it is known that earlier intensive treatments can prevent progression of DN [2, 3]

  • We evaluated Hazard ratios (HR) for renal outcome of DN patients in each pathological class after adjusting for age, sex, body mass index (BMI), estimated glomerular filtration rate (eGFR), mean blood pressure (BP), hemoglobin A1c (HbA1c), grade of albuminuria, urinary red blood cells (RBC), and presence of DM retinopathy

Read more

Summary

Introduction

Diabetic nephropathy (DN) is one of the main causes of end-stage renal disease (ESRD)—and probably among the most challenging kidney diseases—in many countries worldwide [1]. DN is considered a main complication of diabetes when a patient with albuminuria has a history of diabetes longer than 5 years with no or mild hematuria. Renal biopsy is sometimes helpful for patients who have only short histories of diabetes, have no diabetic retinopathy, or do have massive hematuria, since it is known that earlier intensive treatments can prevent progression of DN [2, 3]. Typical findings of DN— e.g., mesangial expansion, arteriolar hyalinosis, and arteriosclerosis—are sometimes observed even in diabetic patients with normo-albuminuria [4, 5]. The impact of the newly proposed pathological classification by the Japan Renal Pathology Society (JRPS) on renal outcome is unclear. We evaluated that impact and created a new pathological scoring to predict outcome using this classification

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call